Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence

References

• Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3):144–54. doi:10.1016/S1473-3099(04)00938-7.
   PubMed Web of Science ®Google Scholar
• Baxter R, Yee A, Aukes L, Snow V, Fireman B, Atkinson B, Klein NP. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016;34(36):4293–97. doi:10.1016/j.vaccine.2016.07.003.
   PubMed Web of Science ®Google Scholar
• Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59(5):615–23. doi:10.1093/cid/ciu348.
   PubMed Web of Science ®Google Scholar
• Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. doi:10.1093/ofid/ofu024.
   PubMedGoogle Scholar
• Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62(2):139–47. doi:10.1093/cid/civ803.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24. doi:10.1016/j.jinf.2012.02.017.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr., Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG. Active bacterial core surveillance program of the emerging infections program network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192(3):377–86. doi:10.1086/431521.
   PubMed Web of Science ®Google Scholar
• Bliss SJ, O’Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H, Levine OS. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis. 2008;8(1):67–80. doi:10.1016/S1473-3099(07)70242-6.
   PubMed Web of Science ®Google Scholar
• Prevnar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Full prescribing information. Collegeville (PA): Pfizer Inc; 2016.
   Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–20. doi:10.1038/nri2494.
   PubMed Web of Science ®Google Scholar
• Pneumovax® 23 (pneumococcal vaccine polyvalent). Full Prescribing Information. Whitehouse Station (NJ): Merck & Co., Inc.; 2015.
   Google Scholar
• Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1):27–35. doi:10.5863/1551-6776-21.1.27.
   PubMedGoogle Scholar
• Farmaki PF, Chini MC, Mangafas NM, Tzanoudaki MT, Piperi CP, Lazanas MZ, Spoulou VS. Immunogenicity and immunological memory induced by the 13-valent pneumococcal conjugate followed by the 23-valent polysaccharide vaccine in HIV-infected adults. J Infect Dis. 2018;218(1):26–34. doi:10.1093/infdis/jiy135.
   PubMed Web of Science ®Google Scholar
• Bennett NM, Pilishvili T, Whitney CG, Moore M, Gierke R, Harris AM. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2013;62(25):521–24.
   Google Scholar
• Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2015;64(34):944–47. doi:10.15585/mmwr.mm6434a4.
   Google Scholar
• Bennett NM, Whitney CG, Moore M, Pilishvili T, Dooling KL. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2012;61:816–19.
   Google Scholar
• Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66(11):1–28. doi:10.15585/mmwr.ss6611a1.
   PubMed Web of Science ®Google Scholar
• Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 2012;18(1):34–40. doi:10.1002/ibd.21668.
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Gulbis AM, Stolar KR, Kebriaei P, Shah DP, McConn KK, Champlin RE, Chemaly RF. Vaccination guidelines after hematopoietic stem cell transplantation: practitioners’ knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014;16(6):878–86. doi:10.1111/tid.12312.
   PubMed Web of Science ®Google Scholar
• Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol. 2011;6(5):1192–97. doi:10.2215/CJN.05430610.
   PubMed Web of Science ®Google Scholar
• Chong PP, Avery RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther. 2017;39(8):1581–98. doi:10.1016/j.clinthera.2017.07.005.
   PubMed Web of Science ®Google Scholar
• De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, et al. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6–17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study. Pediatr Blood Cancer. 2015;62(8):1427–36. doi:10.1002/pbc.25502.
   PubMed Web of Science ®Google Scholar
• Papadatou I, Piperi C, Alexandraki K, Kattamis A, Theodoridou M, Spoulou V. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with beta-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2014;59(6):862–65. doi:10.1093/cid/ciu409.
   PubMed Web of Science ®Google Scholar
• Rezai MS, Ghaffari J, Mahdavi M, Bahari A, Ala S. Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: a randomized clinical trial study. Caspian J Intern Med. 2017;8(1):16–22.
   Web of Science ®Google Scholar
• Nived P, Jorgensen CS, Settergren B. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals. Vaccine. 2015;33(14):1688–94. doi:10.1016/j.vaccine.2015.02.026.
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis. 2015;212(1):18–27. doi:10.1093/infdis/jiu631.
   PubMed Web of Science ®Google Scholar
• Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015;29(11):1345–54. doi:10.1097/QAD.0000000000000689.
   PubMed Web of Science ®Google Scholar
• Sadlier C, O’Dea S, Bennett K, Dunne J, Conlon N, Bergin C. Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial. Sci Rep. 2016;6:32076. doi:10.1038/srep32076.
   PubMed Web of Science ®Google Scholar
• Rossheim AE, Young AM, Siik J, Cunningham TD, Troy SB. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults. Hum Vaccin Immunother. 2016;12(8):2117–23. doi:10.1080/21645515.2016.1160987.
   PubMed Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Fabbiani M, Morandi M, Rossetti B, Tordini G, Cauda R, De Luca A, Di Giambenedetto S, Montagnani F. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study. PLoS One. 2016;11(6):e0156523. doi:10.1371/journal.pone.0156523.
   PubMed Web of Science ®Google Scholar
• Ohtola JA, Saul-McBeth JL, Iyer AS, Leggat DJ, Khuder SA, Khaskhely NM, Westerink MJ. Quantitative and functional antibody responses to the 13-valent conjugate and/or 23-valent purified polysaccharide vaccine in aging HIV-infected adults. J AIDS Clin Res. 2016;7(3). doi:10.4172/2155-6113.1000556.
   Google Scholar
• Ohtola JA, Khaskhely NM, Saul-Mcbeth JL, Iyer AS, Leggat DJ, Khuder SA, Westerink MAJ. Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults. Vaccine. 2016;34(4):451–57. doi:10.1016/j.vaccine.2015.12.013.
   PubMed Web of Science ®Google Scholar
• Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, Hus I, Malm A. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients–preliminary report. PLoS One. 2014;9(12):e114966. doi:10.1371/journal.pone.0114966.
   PubMed Web of Science ®Google Scholar
• Svensson T, Kattstrom M, Hammarlund Y, Roth D, Andersson PO, Svensson M, Nilsson I, Rombo L, Cherif H, Kimby E. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine. 2018;36(25):3701–07. doi:10.1016/j.vaccine.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Andrick B, Alwhaibi A, DeRemer DL, Quershi S, Khan R, Bryan LJ, Somanath PR, Pantin J. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2017;182(5):712–14. doi:10.1111/bjh.14855.
   PubMed Web of Science ®Google Scholar
• Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C. Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant. 2016;51(2):291–94. doi:10.1038/bmt.2015.239.
   PubMed Web of Science ®Google Scholar
• Bahuaud M, Bodilis H, Malphettes M, Maugard Landre A, Matondo C, Bouscary D, Batteux F, Launay O, Fermand JP. Immunogenicity and persistence of the 13-valent pneumococcal conjugate vaccine (PCV13) in patients with untreated smoldering multiple myeloma (SMM): a pilot study. Heliyon. 2017;3(11):e00441. doi:10.1016/j.heliyon.2017.e00441.
   PubMed Web of Science ®Google Scholar
• Shah GL, Shune L, Purtill D, Devlin S, Lauer E, Lubin M, Bhatt V, McElrath C, Kernan NA, Scaradavou A, et al. Robust vaccine responses in adult and pediatric cord blood transplantation recipients treated for hematologic malignancies. Biol Blood Marrow Transplant. 2015;21(12):2160–66. doi:10.1016/j.bbmt.2015.08.010.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >/=2 years: an open-label study. Clin Infect Dis. 2015;61(3):313–23. doi:10.1093/cid/civ287.
   PubMed Web of Science ®Google Scholar
• Small T, Jakubowski AA, Barker JN, Kernan NA, Prockop SE, Scura Iovino C, LeStrange N, Perales MA, Castro-Malaspina H, Koehne G, et al. Safety and immunogenicity of the 13-valent protein-conjugated pneumococcal vaccine (PCV13) following related and unrelated hematopoietic stem cell transplantation (HCT). Blood. 2011;118(21):3037. doi:10.1182/blood.V118.21.3037.3037.
   Web of Science ®Google Scholar
• Kantso B, Halkjaer SI, Thomsen OO, Belard E, Gottschalck IB, Jorgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn’s disease. Vaccine. 2015;33(41):5464–69. doi:10.1016/j.vaccine.2015.08.011.
   PubMed Web of Science ®Google Scholar
• Rakoczi E, Perge B, Vegh E, Csomor P, Pusztai A, Szamosi S, Bodnar N, Szanto S, Szucs G, Szekanecz Z. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine. 2016;83(6):675–79. doi:10.1016/j.jbspin.2015.10.017.
   PubMed Web of Science ®Google Scholar
• Nived P, Nagel J, Saxne T, Geborek P, Jonsson G, Skattum L, Kapetanovic MC. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017;35(29):3639–46. doi:10.1016/j.vaccine.2017.05.044.
   PubMed Web of Science ®Google Scholar
• Nagel J, Saxne T, Geborek P, Bengtsson AA, Jacobsen S, Svaerke Joergensen C, Nilsson JA, Skattum L, Jonsen A, Kapetanovic MC. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017;26(10):1072–81. doi:10.1177/0961203317695465.
   PubMed Web of Science ®Google Scholar
• Caporuscio S, D’Amelio R, Nisini R, Sorgi MLL, Di Rosa R, Salemi S, Laganà B, Canzoni M, Milanetti F, Caldarone E, et al. AB0391 immunogenicity of 13-valent conjugate pneumococcal vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):1023–24. doi:10.1136/annrheumdis-2015-eular.4786.
   Google Scholar
• Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, Mukwaya G, Kaur M, Valdez H. T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J Am Acad Dermatol. 2018;78(6):1149–1155 e1141. doi:10.1016/j.jaad.2017.09.076.
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Nagel J, Nordstrom I, Saxne T, Geborek P, Rudin A. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35(6):903–08. doi:10.1016/j.vaccine.2016.12.068.
   PubMed Web of Science ®Google Scholar
• Sun H, Liu W, Su Y, Ho C, Hu R, Chou N, Wang S, Hsu H, Hung C, Chang S. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) in solid organ transplant (SOT) candidates and recipients. Am J Transplant. 2014;14(suppl 3):770–71. doi:10.1097/00007890-201407151-02634.
   Google Scholar
• Dendle C, Stuart RL, Polkinghorne KR, Balloch A, Kanellis J, Ling J, Kummrow M, Moore C, Thursky K, Buttery J, et al. Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis. 2018;20(2):e12866. doi:10.1111/tid.12866.
   PubMed Web of Science ®Google Scholar
• Mitra S, Stein GE, Bhupalam S, Havlichek DH. Immunogenicity of 13-valent conjugate pneumococcal vaccine in patients 50 years and older with end-stage renal disease and on dialysis. Clin Vaccine Immunol. 2016;23(11):884–87. doi:10.1128/CVI.00153-16.
   PubMedGoogle Scholar
• Liakou CD, Askiti V, Mitsioni A, Stefanidis CJ, Theodoridou MC, Spoulou VI. Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine. 2014;32(12):1394–97. doi:10.1016/j.vaccine.2013.11.106.
   PubMed Web of Science ®Google Scholar
• Rose M, Hey C, Kujumdshiev S, Gall V, Schubert R, Zielen S. Immunogenicity of pneumococcal vaccination of patients with cochlear implants. J Infect Dis. 2004;190(3):551–57. doi:10.1086/422395.
   PubMed Web of Science ®Google Scholar
• Quataert SA, Rittenhouse-Olson K, Kirch CS, Hu B, Secor S, Strong N, Madore DV. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin Diagn Lab Immunol. 2004;11(6):1064–69. doi:10.1128/CDLI.11.6.1064-1069.2004.
   PubMedGoogle Scholar
• Johnson SE, Rubin L, Romero-Steiner S, Dykes JK, Pais LB, Rizvi A, Ades E, Carlone GM. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis. 1999;180(1):133–40. doi:10.1086/314845.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Annex 3: recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. In: World Health Organization, editor. WHO technical report series 977: WHO expert committee on biological standardization, sixtieth report. Geneva (Switzerland): WHO Press; 2013. p. 91–152.
   Google Scholar
• Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19(3):412–25. doi:10.1007/s10156-013-0601-1.
   PubMed Web of Science ®Google Scholar
• Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, Redelman-Sidi G. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687–92. doi:10.1093/cid/ciy175.
   PubMed Web of Science ®Google Scholar
• Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–12. doi:10.1002/art.21386.
   PubMed Web of Science ®Google Scholar
• Gupta S, Brennan DC. Pneumococcal 13-valent conjugate vaccine (Prevnar 13)-associated immune thrombocytopenic purpura in a renal transplant recipient: a case report. Transplant Proc. 2016;48(1):262–64. doi:10.1016/j.transproceed.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Averbuch D, Maury S, Engelhard D. Pneumococcal immunization in immunocompromised hosts: where do we stand? Expert Rev Vaccines. 2014;13(1):59–74. doi:10.1586/14760584.2014.859990.
   PubMed Web of Science ®Google Scholar
• Fletcher MA, Balmer P, Bonnet E, Dartois N. PCVs in individuals at increased risk of pneumococcal disease: A literature review. Expert Rev Vaccines. 2015;14(7):975–1030. doi:10.1586/14760584.2015.1037743.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498–506. doi:10.1093/cid/ciy312.
   PubMed Web of Science ®Google Scholar